Bone morphogenetic proteins (BMPs) belong to the transforming growth factor-β (TGF-β) family signalling pathway. Similar to TGF-β, the complex roles of BMPs in development and disease are demonstrated by their dichotomous roles in various cancers and cancer stages. Although early studies implicated BMP signalling in tumour suppressive phenotypes, the results of more recent experiments recognize BMPs as potent tumour promoters. Many of these complexities are becoming illuminated by understanding the role of BMPs in their contextual role in unique cell types of cancer and the impact of their surrounding tumour microenvironment. Here we review the emerging roles of BMP signalling in cancer, with a focus on the molecular underpinnings of BMP signalling in individual cancers as a valid therapeutic target for cancer prevention and treatment.
Skip Nav Destination
Article navigation
August 2016
-
Cover Image
Cover Image
A schematic representation of TGF-β and BMP9 signalling in endothelial cells via their serine/threonine type I and type II receptors, co-receptor endoglin and downstream Smad intracellular proteins. Taken from the article ‘Targeting tumour vasculature by inhibiting activing receptor-like kinase (ALK)1 function’ by de Vinuesa et al. in this issue (volume 44, issue 4, pages 1142-1149). - PDF Icon PDF LinkTable of Contents
Review Article|
August 15 2016
Emerging roles of the bone morphogenetic protein pathway in cancer: potential therapeutic target for kinase inhibition
Pawina Jiramongkolchai;
Pawina Jiramongkolchai
*Department of Medicine, Pharmacology, and Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, U.S.A.
Search for other works by this author on:
Philip Owens;
Philip Owens
1
†Department of Cancer Biology, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 U.S.A.
1Correspondence may be addressed to either of these authors (email charles.c.hong@vanderbilt.edu or Philip.owens@vanderbilt.edu).
Search for other works by this author on:
Charles C. Hong
Charles C. Hong
1
*Department of Medicine, Pharmacology, and Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, U.S.A.
‡Research Medicine, Veterans Affairs Tennessee Valley Healthcare System, Nashville, TN 37212, U.S.A.
1Correspondence may be addressed to either of these authors (email charles.c.hong@vanderbilt.edu or Philip.owens@vanderbilt.edu).
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
March 04 2016
Online ISSN: 1470-8752
Print ISSN: 0300-5127
© 2016 The Author(s). published by Portland Press Limited on behalf of the Biochemical Society
2016
Biochem Soc Trans (2016) 44 (4): 1117–1134.
Article history
Received:
March 04 2016
Citation
Pawina Jiramongkolchai, Philip Owens, Charles C. Hong; Emerging roles of the bone morphogenetic protein pathway in cancer: potential therapeutic target for kinase inhibition. Biochem Soc Trans 15 August 2016; 44 (4): 1117–1134. doi: https://doi.org/10.1042/BST20160069
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Captcha Validation Error. Please try again.